A biomarker study of TDP-43 for the treatment of Alzheimer's disease
Latest Information Update: 19 Apr 2023
At a glance
- Drugs Celecoxib/ciprofloxacin (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- Sponsors NeuroSense Therapeutics
Most Recent Events
- 17 Apr 2023 According to a NeuroSense Therapeutics media release, data are now being evaluated and results from this trial expected by the first week of May.
- 23 Jan 2023 New trial record
- 19 Jan 2023 Positive preliminary results published in the NeuroSense Therapeutics Media Release.